Our research builds on existing biomarker discovery and development across Manchester.
The Stoller Biomarker Discovery Centre (SBDC) and the Manchester Molecular Pathology Innovation Centre (MMPathIC), co-located at Citylabs in the heart of the clinical campus, form a hub of innovative activity aimed at furthering personalised and stratified medicine approaches.
This activity builds upon the existing funded research already ongoing across the city, with inflammatory disease and cancer being particular areas of strength.
For example, Manchester plays a leading role in three Medical Research Council Stratified Medicine consortia in psoriasis, systemic lupus erythematosus and rheumatoid arthritis, demonstrating our strengths in inflammatory disease.
Manchester hosts one of only two Cancer Research UK (CRUK) Major Centres in the country. Biomarker discovery, validation and clinical qualification is a key theme within the centre, with a particular focus on liquid biopsy.